Modulators of complex I

US11795147B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-11795147-B2
Application numberUS-202017002937-A
CountryUS
Kind codeB2
Filing dateAug 26, 2020
Priority dateAug 26, 2019
Publication dateOct 24, 2023
Grant dateOct 24, 2023

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I)

First claim

Opening claim text (preview).

The invention claimed is: 1. A compound having formula (I) or a salt thereof wherein: R1 is C 1-4 -alkyl unsubstituted or substituted with MeO; tetrahydropyranyl, tetrahydrofuranyl, oxetanyl, dioxepanyl, pyrrolidinyl or piperidinyl; or pyrrolidinyl or piperidinyl with the nitrogen substituted by methyl, isopropyl, oxetanyl, ethoxycarbonyl, acetyl, or trifluoroacetyl; R2 is a 5-, 6- or 7-membered ring containing 1 or 2 heteroatoms selected from O or N bound in formula (I) by a C═C double bond, in which one or both N-atoms can be substituted by methyl, isopropyl, acetyl, benzyloxycarbonyl, phenyl, oxetanyl or tetrahydropyranyl, and in which one or more C-atoms can be substituted by -methyl or —OH; R3 and R4 are independently from one another hydrogen; C 1-6 -alkyl, unsubstituted or substituted with one or more F, methoxy, C 3-8 -cycloalkyl unsubstituted or substituted with one or more F; aryl; heteroaryl consisting of 5 to 6 ring atoms; or heterocyclyl selected from the group consisting of oxetanyl, tetrahydropyranyl and pyrrolidinyl, said heterocyclyl being unsubstituted or substituted with C 1-6 -alkyl, acetyl, tetrahydrofuranyl, oxetanyl or hydroxyethylacetyl; or R3 and R4 together with the attached N form a heterocyclyl ring selected from the group consisting of morpholinyl and pyrrolidinyl both unsubstituted or substituted with C 1-6 -alkyl, F, or hydroxyl; or R3 and R4 together represent one of the following groups: 2. A compound selected from the group consisting of the following compounds 1 to 175, or a salt thereof: # Structure  1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18

Assignees

Inventors

Classifications

  • C07D207/38Primary

    2-Pyrrolones · CPC title

  • directly linked by a ring-member-to-ring-member bond · CPC title

  • Bridged systems · CPC title

  • with only one oxygen atom as ring hetero atom in the oxygen-containing ring · CPC title

  • Spiro-condensed systems · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US11795147B2 cover?
The present invention describes compounds modulating the function of mitochondrial complex I (NADH-quinone oxidoreductase) having formula (I)
Who is the assignee on this patent?
Boehringer Ingelheim Int
What technology area does this patent fall under?
Primary CPC classification C07D207/38. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue Oct 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).